California SJS Lawyer: Carbamazepine (Tegretol) Stevens-Johnson Syndrome Claims

What Is SJS/TEN and Why Carbamazepine Is Implicated

Stevens-Johnson Syndrome (SJS) and its more severe form, Toxic Epidermal Necrolysis (TEN), are rare but serious adverse drug reactions characterized by painful skin detachment, mucous membrane involvement, and potential systemic complications. Carbamazepine (Tegretol), an anticonvulsant used for epilepsy, trigeminal neuralgia, and mood stabilization, has long been associated with heightened risk of SJS/TEN, particularly early in therapy and in certain genetically predisposed populations. U.S. prescribing information includes boxed warnings addressing serious dermatologic reactions and genetic testing considerations. See the FDA label for Tegretol and the generic carbamazepine labeling: FDA Tegretol Prescribing Information (2024); DailyMed Carbamazepine.

Warning Labels, Genetic Risk, and Medical Context

The FDA-approved labeling for carbamazepine warns of serious and sometimes fatal dermatologic reactions, including SJS/TEN, and discusses increased risk associated with specific HLA alleles (e.g., HLA-B1502 in certain Asian populations and HLA-A3101 in others). It also addresses the role of genetic testing prior to initiation in at-risk populations. These warnings can be important in litigation to show what risks were known, what was communicated to prescribers under the learned intermediary doctrine, and whether warnings were adequate at the time of use. Sources: FDA Tegretol Label; DailyMed.

Potential Legal Theories in California

• Failure to warn (primary pathway): California recognizes failure-to-warn claims for prescription drugs, evaluated under the learned intermediary doctrine. See Carlin v. Superior Court (1996) 13 Cal.4th 1104.
• Design defect (limited): California generally bars strict-liability design-defect claims for properly prepared prescription drugs accompanied by adequate warnings. See Brown v. Superior Court (1988) 44 Cal.3d 1049. Negligence-based theories may still be asserted depending on the facts.
• Manufacturing defect: Claims may arise if a particular lot or product deviated from intended specifications.
• Negligence: Allegations can include negligent testing, pharmacovigilance, or communication of safety information.
• Breach of warranty / misrepresentation: Where supported by marketing or labeling statements.
• Medical negligence: Separate claims may involve prescribing decisions, failure to advise of known risks, or delayed recognition/referral when early SJS/TEN symptoms appeared.

Preemption and brand/generic distinctions: Federal preemption limits many claims against generic manufacturers (e.g., failure-to-warn and design-defect theories). See PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011) and Mutual Pharmaceutical Co. v. Bartlett, 570 U.S. 472 (2013). Failure-to-warn claims against brand manufacturers may proceed in some circumstances. See Wyeth v. Levine, 555 U.S. 555 (2009). California also recognizes certain innovator liability theories against brand manufacturers in limited circumstances even when the plaintiff ingested a generic, depending on the facts and timing. See T.H. v. Novartis Pharmaceuticals Corp. (2017) 4 Cal.5th 145.

What To Do If SJS/TEN Is Suspected

Immediate medical care is critical. If safe and feasible, preserve:

• Medication details: brand/generic names, doses, start/stop dates, prescriber, and pharmacy.
• Original packaging and pharmacy labels.
• Photos of skin/mucosal findings; hospitalization and pathology records.
• Any genetic testing results.
• Notes or messages about risk discussions, warnings, and consent.

Prompt documentation helps both medical management and potential legal evaluation.

Evidence That Often Matters

• Prescribing records and physician notes regarding risk counseling (learned intermediary context).
• The exact FDA-approved label and Medication Guide in effect when you started carbamazepine.
• Pharmacy counseling records and written materials you received.
• Hospital and pathology records confirming SJS/TEN and addressing differentials.
• Adverse event timelines relative to initiation, dose changes, or re-challenge.
• Expert analyses on causation and adequacy of warnings.

Who May Be Liable

Depending on the facts, potential defendants can include the brand or generic manufacturer, distributors, and sometimes healthcare providers. California treats innovator and generic liability differently, with federal preemption affecting many generic-drug claims (Mensing; Bartlett) and California recognizing limited innovator liability against brand manufacturers in certain circumstances (T.H. v. Novartis). A tailored assessment is needed to identify proper parties.

Damages in SJS/TEN Cases

Recoverable damages in successful cases may include medical expenses, lost income, pain and suffering, disfigurement, future care costs (e.g., ocular complications, scarring, rehabilitation), and, where supported by the facts and law, punitive damages. In wrongful death matters, eligible heirs may pursue appropriate claims.

Filing Considerations in California

California imposes strict deadlines that vary by claim type and party:

• General personal injury/product liability: often two years (subject to discovery rules). See Code Civ. Proc. § 335.1.
• Medical malpractice: generally one year from discovery or three years from injury, whichever occurs first (with exceptions). See Code Civ. Proc. § 340.5.
• Claims involving California public entities: claim presentation typically within six months. See Gov. Code § 911.2.

Deadlines can be complex and fact-dependent. Speak with counsel promptly to protect your rights.

How Our California SJS Lawyer Can Help

We investigate medication histories, obtain the labeling in effect at the time of use, consult medical and pharmacology experts, and evaluate potential liability across manufacturers and prescribers. We coordinate with treating physicians to document ongoing complications, including ophthalmologic and dermatologic sequelae. Many firms offer no-cost initial consultations and may handle cases on a contingency fee where permitted.

FAQ

Do I have a claim if I took generic carbamazepine?

Possibly, but many claims against generics face federal preemption barriers. A lawyer can assess alternative avenues and any potential claims against brand manufacturers under California law, depending on the facts and timing.

How soon should I contact a lawyer?

As soon as possible. California deadlines can be short and fact-specific, and early evidence preservation is crucial.

What if I was not warned about SJS/TEN?

Failure-to-warn claims focus on what was communicated to prescribers and patients in light of then-current labeling and knowledge. Records of counseling and materials provided are key.

Can I recover for future eye care and scarring?

Yes, where supported by evidence, damages can include future medical care, pain and suffering, disfigurement, and related losses.

Next Steps

If you or a loved one suffered SJS/TEN after taking carbamazepine or Tegretol in California, contact an attorney experienced in pharmaceutical litigation as soon as possible. Bringing your medication list, pharmacy receipts, and hospital records to an initial consultation can accelerate case evaluation. Request a free case review.

Disclaimer (California): This post provides general information for California matters and is not legal or medical advice. Reading it does not create an attorney–client relationship. Laws and deadlines change and vary by facts. Consult a qualified California attorney about your situation.